PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

Clinical Pharmacology in Drug Development

Volumn 4, Issue 2, 2015, Pages 89-98

  Wang, Diane D ^a   Li, Chunze ^a   Sun, Wan ^a   Zhang, Shuzhong ^a   Shalinsky, David R ^a   Kern, Kenneth A ^a   Curtin, Nicola J ^b   Sam, Wai Johnn ^a   Kirkpatrick, Tanya R ^a   Plummer, Ruth ^b  

^a PFIZER INC   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Mixed effects modeling; biomarker; Pharmacokinetics (PK) pharmacodynamics (PD); Poly (ADP ribose) polymerase (PARP); Rucaparib

Indexed keywords

RUCAPARIB; TEMOZOLOMIDE; BIOLOGICAL MARKER; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FIRST IN HUMAN STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; LIMIT OF QUANTITATION; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL LYMPHOCYTE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; SOLID TUMOR; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPUTER SIMULATION; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; NEOPLASM;

BIOMARKERS; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; LYMPHOCYTES; MODELS, BIOLOGICAL; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84924989774     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.176     Document Type: Article

References (13)

1. Floyd E. McShane TM. Development and use of biomarkers in oncology drug development. Toxicol Pathol. 2004; 32 (Suppl. 1):106-115.
2. Ratain RJ. Glassman RH. Biomarkers in phase I oncology trials: signal noise, or expensive distraction?. Clin Cancer Res. 2007; 13:6545-6548.
3. Yelamos J. Farres J. Llacuna L, et al. PARP-1 and PARP-2: New players in tumour development. Am J Cancer Res. 2011; 1(3):328-346.
4. Annunziata CM. O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res. 2010; 16:4517-4526.
5. Plummer R. Jones C. Middleton M, et al. Phase I study of the Poly (ADP-Ribose) polymerase Inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2005; 14:7917-7923.
6. Kummar S. Kinders R. Gutierrez KR, et al. Phase 0 clinical trial of the poly (ADP-Ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009; 27:2705-2711.
7. Fong PC. Boss DS. Yap TA, et al. Inhibition of poly (ADP-Ribose) polymerase in tumors from BRCA mutation carriers. NEJM. 2009; 361:123-134.
8. Tutt A. Robson M. Garber J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol. 2009; 27:CRA501.
9. Audeh MW. Carmichael J. Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010; 376:245-251.
10. Bundred N. Gardovskis J. Jaskiewicz J, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: A Phase 1 multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs. 2013; 31:949-958.
11. Ahn JE. Karlsson MO. Dunne A. Ludden TM. Likelihood based approaches to handling data below the quantification limits using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008; 35:401-421.
12. Wang DD. Zhang S. Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol. 2012; 52:39-54.
13. Zaremba T. Thomas H. Cole M. Plummer ER. Curtin NJ. Doxorubicin-induced suppression of poly (ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemother Pharmacol. 2010; 66(4):807-812.